<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 17.5: Persistent Pathogens: Reactivated EBV and Molecular Mimicry</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE theme for Complex Scenarios */
        .module-header {
            background: linear-gradient(135deg, #6d28d9 0%, #8b5cf6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #6d28d9;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #6d28d9;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #6d28d9;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #8b5cf6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #6d28d9;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d1d5db;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #6d28d9;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #8b5cf6;
        }

        .term-item .term {
            font-weight: 700;
            color: #6d28d9;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #6d28d9;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #4c1d95;
            margin: 30px 0 15px 0;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #6d28d9;
            font-weight: 700;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #6d28d9 0%, #8b5cf6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #8b5cf6, #6d28d9);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 16px;
        }

        th {
            background: #f9fafb;
            padding: 15px;
            text-align: left;
            border-bottom: 2px solid #e5e7eb;
            color: #6d28d9;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 36px;
            font-weight: 700;
            margin-bottom: 8px;
            display: block;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #d97706;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #fde68a;
        }

        .reveal-btn {
            background: #d97706;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #fef3c7;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.8;
        }

        @media (max-width: 768px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 17: Complex Client Scenarios</p>
            <h1 class="lesson-title">Lesson 5: Persistent Pathogens: Reactivated EBV and Molecular Mimicry</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 5 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#viral-trigger"><span class="section-num">1</span>The Viral Trigger: EBV & Hashimoto's</a></li>
                <li><a href="#molecular-mimicry"><span class="section-num">2</span>The Mechanics of Molecular Mimicry</a></li>
                <li><a href="#identifying-reactivation"><span class="section-num">3</span>Advanced Viral Panel Interpretation</a></li>
                <li><a href="#immune-modulation"><span class="section-num">4</span>Strategies for Viral Latency</a></li>
                <li><a href="#fatigue-distinction"><span class="section-num">5</span>Thyroid vs. Post-Viral Fatigue</a></li>
                <li><a href="#clinical-application"><span class="section-num">6</span>Case Studies & Coaching Protocols</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Explain the physiological link between Epstein-Barr Virus (EBV) and the "Address Hashimoto's" (A) pillar of the B.A.L.A.N.C.E. Thyroid Methodâ„¢.</li>
                <li>Identify the specific viral proteins that trigger molecular mimicry in thyroid tissue.</li>
                <li>Interpret advanced EBV antibody markers to distinguish between past infection and active reactivation.</li>
                <li>Develop immune-modulating coaching strategies to support viral latency through nutrition and lifestyle.</li>
                <li>Differentiate between metabolic thyroid fatigue and immune-driven post-viral fatigue.</li>
            </ul>
        </div>

        <p>In our journey through the B.A.L.A.N.C.E. Thyroid Methodâ„¢, we often encounter the "stuck" clientâ€”someone who has optimized their nutrition, cleared environmental toxins, and balanced their minerals, yet still experiences high antibody titers and debilitating fatigue. As we explored in previous lessons on mold and SIBO, these subclinical obstacles often hide in the immune system's blind spots. Today, we focus on one of the most prevalent yet overlooked triggers in the "Address Hashimoto's" (A) protocol: <span class="highlight">Epstein-Barr Virus (EBV)</span>.</p>

        <h2 id="viral-trigger">1. The Viral Trigger: EBV & Hashimoto's</h2>
        <p>Epstein-Barr Virus is a member of the herpesvirus family (HHV-4) and is nearly ubiquitous in the adult population. While most individuals contract EBV in childhood or adolescence and move it into a permanent <span class="highlight">latent phase</span>, those with autoimmune predispositions often struggle with <span class="highlight">lytic reactivation</span>.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">81%</span>
                    <span class="stat-label">EBV Presence in Hashimoto's Tissue</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">95%</span>
                    <span class="stat-label">Adults Carrying EBV</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">15x</span>
                    <span class="stat-label">Increased Risk with Active EA</span>
                </div>
            </div>
        </div>

        <p>A landmark study published in the journal <i>Pathogens</i> found that EBV was present in <span class="stat-highlight">81% of thyroid specimens</span> from patients with Hashimoto's, compared to only 10% of healthy controls (Janegova et al., 2013). This suggests that the virus isn't just a bystander; it may actively reside within the thyroid gland itself, acting as a "living" adjuvant that keeps the immune system in a state of perpetual alarm.</p>

        <h2 id="molecular-mimicry">2. The Mechanics of Molecular Mimicry</h2>
        <p>Molecular mimicry occurs when the immune system identifies a foreign pathogen (like a virus) but, due to structural similarities, begins attacking the body's own tissues. In the case of EBV, the <span class="highlight">EBNA-1 protein</span> (Epstein-Barr Nuclear Antigen 1) shares a significant amino acid sequence homology with <span class="highlight">Thyroid Peroxidase (TPO)</span>.</p>

        <p>When the virus reactivates, the immune system produces B-cells to target EBNA-1. However, because of the "mimicry," these same antibodies cross-react with TPO in the thyroid gland. This is why a client may experience a "flare" during times of high stress or illnessâ€”the stress triggers viral replication, which in turn triggers an autoimmune attack on the thyroid.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Plateau" Client</p>
                    <p class="subtitle">Sarah, 42 | Hashimoto's Diagnosis 4 Years Prior</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah G.</h4>
                        <p>Symptoms: Crushing afternoon fatigue, "brain fog," and TPO antibodies plateaued at 450 IU/mL despite strict AIP diet.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Sarah had followed the "A" (Address Hashimoto's) protocol via diet but hadn't investigated pathogens. We suggested she ask her doctor for a 4-marker EBV panel.</p>
                <p><strong>Outcomes:</strong> Results showed an <span class="stat-highlight">Early Antigen (EA) IgG of 4.2 (Positive > 1.0)</span>, indicating active reactivation. After 12 weeks of immune modulation (Monolaurin, L-Lysine, and Selenium optimization), her EA dropped to negative, and her TPO antibodies fell to 85 IU/mL. Her energy levels restored by 70%.</p>
            </div>
        </div>

        <h2 id="identifying-reactivation">3. Advanced Viral Panel Interpretation</h2>
        <p>Standard labs often only test for "Past Infection" (VCA IgG), leading many clinicians to tell clients their EBV is "fine." As a specialized coach, you must understand the nuances of the 4-marker panel to identify <span class="highlight">chronic active reactivation</span>.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Meaning</th>
                        <th>Significance in Thyroid Health</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>VCA IgM</strong></td>
                        <td>Viral Capsid Antigen (Acute)</td>
                        <td>Indicates a brand-new infection (Mono). Rare in chronic thyroid cases.</td>
                    </tr>
                    <tr>
                        <td><strong>VCA IgG</strong></td>
                        <td>Viral Capsid Antigen (Past)</td>
                        <td>Indicates the client has the virus. 95% of adults are positive. Alone, it means little.</td>
                    </tr>
                    <tr>
                        <td><strong>EBNA IgG</strong></td>
                        <td>Nuclear Antigen</td>
                        <td>Indicates the virus is in the latent (sleeping) phase. Usually positive in healthy individuals.</td>
                    </tr>
                    <tr>
                        <td><strong>EA-D IgG</strong></td>
                        <td>Early Antigen</td>
                        <td><strong>The Smoking Gun.</strong> Indicates the virus is currently replicating (waking up). This is the primary driver of flares.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="immune-modulation">4. Strategies for Viral Latency</h2>
        <p>In the B.A.L.A.N.C.E. Thyroid Methodâ„¢, we don't "kill" viruses (which is impossible); we <span class="highlight">modulate the host environment</span> to force the virus back into latency. This involves shifting the immune system from a Th1/Th2 imbalance toward regulatory T-cell (Treg) dominance.</p>

        <h3>Nutritional Catalysts for Latency</h3>
        <ul>
            <li><strong>L-Lysine:</strong> Competes with Arginine, which EBV requires for replication. Target: 1,000â€“3,000mg daily during flares.</li>
            <li><strong>Selenium:</strong> As discussed in Module 5, Selenium is a potent inhibitor of viral expression and reduces TPO antibodies specifically in EBV-positive patients.</li>
            <li><strong>Monolaurin:</strong> A derivative of lauric acid that dissolves the lipid envelope of the virus, making it harder for the virus to enter cells.</li>
            <li><strong>Polyphenols (Luteolin & Quercetin):</strong> These inhibit the "Immediate Early" genes of EBV, preventing the virus from starting its replication cycle.</li>
        </ul>

        <h2 id="fatigue-distinction">5. Thyroid vs. Post-Viral Fatigue</h2>
        <p>One of the most valuable skills you can offer as a coach is helping a client differentiate between metabolic fatigue and immune-driven fatigue. This ensures that the "Energy Restoration" (E) phase of the protocol is tailored correctly.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Metabolic (Thyroid) Fatigue</th>
                        <th>Post-Viral (EBV) Fatigue</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Timing</strong></td>
                        <td>Heavy in the morning; improves slightly with movement.</td>
                        <td>"Crashing" after exertion (Post-Exertional Malaise).</td>
                    </tr>
                    <tr>
                        <td><strong>Temperature</strong></td>
                        <td>Consistently low basal body temp (< 97.8Â°F).</td>
                        <td>Feeling "feverish" or "chilled" without a true fever.</td>
                    </tr>
                    <tr>
                        <td><strong>Lymph Nodes</strong></td>
                        <td>Unchanged.</td>
                        <td>Tenderness in neck or armpits during flares.</td>
                    </tr>
                    <tr>
                        <td><strong>Sleep</strong></td>
                        <td>Waking unrefreshed but functional.</td>
                        <td>Waking feeling like they have "the flu."</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="clinical-application">6. Clinical Application & Coaching Protocols</h2>
        <p>When working with a client suspected of EBV reactivation, your coaching should pivot to <span class="highlight">nervous system regulation</span>. Stress (cortisol) is the #1 trigger for EBV reactivation. If the "L" (Lifestyle) pillar of B.A.L.A.N.C.E. is ignored, no amount of lysine will keep the virus dormant.</p>

        <h3>The Viral-Thyroid Protocol Steps:</h3>
        <ol>
            <li><strong>Screening:</strong> Encourage the 4-marker EBV panel if antibodies are stuck or PEM (Post-Exertional Malaise) is present.</li>
            <li><strong>Arginine/Lysine Ratio:</strong> Temporarily reduce high-arginine foods (nuts, seeds, chocolate) while increasing lysine-rich foods (wild-caught fish, organic poultry).</li>
            <li><strong>Mitochondrial Support:</strong> EBV hijacks mitochondrial machinery. CoQ10 and PQQ can help protect the "E" (Energy) pillar during a flare.</li>
            <li><strong>Pacing:</strong> Implement "Energy Envelope" coachingâ€”ensuring the client does not push through viral fatigue, which can lead to long-term "crashes."</li>
        </ol>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Which EBV marker is the most significant indicator that the virus is actively contributing to a Hashimoto's flare?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">The <strong>Early Antigen (EA-D) IgG</strong>. A positive EA-D indicates the virus is in the lytic phase (replicating), which triggers molecular mimicry and immune cross-reactivity with thyroid tissue.</div>
            </div>
            <div class="question-item">
                <p class="question-text">2. How does the EBNA-1 protein contribute to Hashimoto's pathophysiology?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Through <strong>Molecular Mimicry</strong>. EBNA-1 shares structural similarities with Thyroid Peroxidase (TPO). Antibodies meant to target the virus mistakenly attack the thyroid gland.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>EBV is a primary subclinical obstacle in the "Address Hashimoto's" (A) pillar of the B.A.L.A.N.C.E. Thyroid Methodâ„¢.</li>
                <li>Molecular mimicry between EBNA-1 and TPO explains why viral flares correlate with antibody spikes.</li>
                <li>A standard VCA IgG test is insufficient; coaches should look for the 4-marker panel including Early Antigen (EA).</li>
                <li>Immune modulation via L-Lysine, Selenium, and stress management is the gold standard for restoring viral latency.</li>
                <li>Differentiating metabolic fatigue from post-viral fatigue is essential for proper energy restoration (E) strategies.</li>
            </ul>
        </div>

        <div class="references-box">
            <p class="box-label">References & Further Reading</p>
            <ul>
                <li>Janegova, A., et al. (2013). "The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases." <i>Pathogens</i>.</li>
                <li>Dittfeld, A., et al. (2016). "A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders." <i>Central European Journal of Immunology</i>.</li>
                <li>Cusick, M. F., et al. (2012). "Molecular Mimicry as a Mechanism of Autoimmune Disease." <i>Clinical Reviews in Allergy & Immunology</i>.</li>
                <li>Vojdani, A. (2014). "A Potential Link between Environmental Triggers and Autoimmunity." <i>Autoimmune Diseases</i>.</li>
                <li>Lo, A. K., et al. (2013). "Epstein-Barr virus (EBV)-encoded RNA promotes immune cell infiltration and antibody production in thyroid tissue." <i>Journal of Virology</i>.</li>
                <li>Prabhakar, B. S., et al. (2003). "Role of viruses in the etiology of thyroid diseases." <i>Reviews in Endocrine and Metabolic Disorders</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Â© 2024</p>
            <p class="copyright">Premium Certification Content | B.A.L.A.N.C.E. Thyroid Methodâ„¢</p>
        </footer>
    </div>
</body>

</html>